Short-Course Blinatumomab for B-Cell Leukemia
Author Information
Author(s): Yin Jin, Cai Xiaoya, Qian Bingxin, Liu Ying, Li Dengju
Primary Institution: Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology
Hypothesis
Can short-course blinatumomab treatment effectively bridge patients with relapsed/refractory B-cell acute lymphoblastic leukemia to further salvage therapy?
Conclusion
Short-course blinatumomab treatment can provide significant clinical benefits and is a viable alternative for cost-efficient management of relapsed/refractory B-cell acute lymphoblastic leukemia.
Supporting Evidence
- 83.3% of patients achieved morphological complete remission.
- 40% of patients were minimal residual disease-negative.
- Estimated 2-year overall survival rate was 82.62%.
- Estimated 2-year progression-free survival rate was 78.35%.
- Patients receiving further treatment had significantly better outcomes.
Takeaway
This study shows that a shorter treatment with blinatumomab can help patients with a type of blood cancer feel better and get ready for more treatments without spending too much money.
Methodology
Retrospective analysis of clinical data from 30 patients treated with short-course blinatumomab between 2021 and 2022.
Limitations
The study had a limited number of patients and was retrospective in nature.
Participant Demographics
Median age was 38 years, with 14 men and 16 women.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95%CI 63.14–92.37 for OS, 95%CI 57.79–89.71 for PFS
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website